Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,053 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching placebo; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more

Conditions: Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
Interventions: Influenza vaccine; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 3 Years to 22 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: East Setauket, New York

Conditions: Angioedema
Interventions: Placebo, Lanadelumab; Other · Drug
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more

Conditions: Atopic Dermatitis
Interventions: Hydrogel vehicle, Eucerin Lotion; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Familial Cold Autoinflammatory Syndrome
Interventions: DFV890; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Atopic Dermatitis
Interventions: Ustekinumab, Placebo; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Atopic Dermatitis, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 121
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Moisturizer with each subject's own antimicrobial bacteria; Biological
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis
Interventions: Crisaborole, Tacrolimus 0.03% Ointment; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 2 Years to 15 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Tdap vaccine, PPS vaccine; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more

Conditions: Atopic Dermatitis
Interventions: PF-07275315, PF-07264660, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 50
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 42 more

Conditions: Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Dermatitis, Atopic
Interventions: P3-Fast, Comm-Fast, Vari-Fast, Comm-Fed; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bacterial Infections
Interventions: Debio 1450 IV, Debio 1450 Oral, Linezolid, Debio 1450 Oral Placebo, Linezolid Placebo, Vancomycin IV; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 17 more

Conditions: Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions: N/A This is an observational study; Other
Lead sponsor: OM1, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Dupilumab SAR231893; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hereditary Angioedema
Interventions: CINRYZE; Biological
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 7
States / cities: Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Psoriasis, Atopic Dermatitis
Interventions: Blood pressure, Height, Weight, BMI, Waist Circumference; Other
Lead sponsor: Northwestern University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: San Diego, California • San Francisco, California • Stanford, California + 6 more

Conditions: Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: RVT-501 0.5% topical ointment; Drug
Lead sponsor: Dermavant Sciences GmbH; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more

Conditions: Sun Sensitivity, Sun Protection, Skin Cancer
Interventions: Sun Protection Program; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Flu Vaccine Response in Patients on Biologic Therapies

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

Reproductive Health in Men and Women With Vasculitis

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Vasculitis Illness Perception (VIP) Study

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

Study of Debio 1450 for Bacterial Skin Infections

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Helping Children be Safe Outdoors With Sun Protection